N2OFF, Inc. (NXTS)
Oxford Ledge is still expanding full research coverage of NXTS. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Nexentis Technologies is a holding company focused on cancer biotechnology through MitoCareX and renewable energy projects through Solterra.
Source: 10-K
SEC filings
- S-1 IPO / securities registration statement 2026-07-13
- 8-K Entry into material agreement; 3.02; Financial statements and exhibits 2026-06-22
- 8-K Entry into material agreement; 3.02; Financial statements and exhibits 2026-06-12
- 8-K Entry into material agreement; Creation of direct financial obligation; Financial statements and exhibits 2026-05-27
- 10-Q Quarterly financial report (unaudited) 2026-05-14
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for NXTS. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open NXTS in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.